Cite
Lycorine suppresses the malignancy of breast carcinoma by modulating epithelial mesenchymal transition and β-catenin signaling.
MLA
Sun, Yanfang, et al. “Lycorine Suppresses the Malignancy of Breast Carcinoma by Modulating Epithelial Mesenchymal Transition and β-Catenin Signaling.” Pharmacological Research, vol. 195, Sept. 2023, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.phrs.2023.106866.
APA
Sun, Y., Gu, Y., Gao, X., Jin, X., Wink, M., Sharopov, F. S., Yang, L., & Sethi, G. (2023). Lycorine suppresses the malignancy of breast carcinoma by modulating epithelial mesenchymal transition and β-catenin signaling. Pharmacological Research, 195, N.PAG. https://doi.org/10.1016/j.phrs.2023.106866
Chicago
Sun, Yanfang, Yi Gu, Xiaoyan Gao, Xiaoyan Jin, Michael Wink, Farukh S. Sharopov, Linjun Yang, and Gautam Sethi. 2023. “Lycorine Suppresses the Malignancy of Breast Carcinoma by Modulating Epithelial Mesenchymal Transition and β-Catenin Signaling.” Pharmacological Research 195 (September): N.PAG. doi:10.1016/j.phrs.2023.106866.